Nifty
:
22410.60
Sensex
:
73902.89
74.20 (0.33%)
814.56 (1.11%)
Nifty
Sensex
:
:
22410.60
73902.89
74.20 (0.33%)
814.56 (1.11%)

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 533573 | NSE: APLLTD

NSE BSE
952.10
22-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  940.00
  •  959.85
  •  940.00
  •  938.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  61662
  •  585.63
  •  1094.00
  •  532.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 18,566.37
  • 31.24
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 19,202.95
  • 0.85%
  • 3.96

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.61%
  • 0.30%
  • 7.41%
  • FII
  • DII
  • Others
  • 4.46%
  • 14.92%
  • 3.30%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.74
  • 7.51
  • 1.58

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.09
  • -3.72
  • -13.71

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.80
  • -10.44
  • -32.56

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.83
  • 19.32
  • 28.32

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.12
  • 3.39
  • 2.95

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.77
  • 14.79
  • 16.05

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
1,630.57
1,509.02
8.05%
1,594.93
1,475.01
8.13%
1,486.15
1,262.14
17.75%
1,406.45
1,415.74
-0.66%
Expenses
1,364.21
1,260.26
8.25%
1,386.69
1,242.27
11.63%
1,287.46
1,247.49
3.20%
1,194.23
1,255.64
-4.89%
EBITDA
266.36
248.76
7.08%
208.24
232.74
-10.53%
198.69
14.65
1,256.25%
212.22
160.10
32.55%
EBIDTM
16.34%
16.48%
13.06%
-4.88%
13.37%
1.16%
15.09%
11.31%
Other Income
2.89
0.44
556.82%
10.15
0.33
2,975.76%
11.67
1.08
980.56%
0.89
10.27
-91.33%
Interest
15.17
14.60
3.90%
15.69
12.41
26.43%
14.39
8.79
63.71%
14.37
6.70
114.48%
Depreciation
69.45
66.51
4.42%
67.56
67.70
-0.21%
66.18
67.10
-1.37%
74.12
123.08
-39.78%
PBT
184.63
168.09
9.84%
135.14
152.96
-11.65%
129.79
-60.16
-
124.62
40.59
207.02%
Tax
4.13
32.57
-87.32%
-1.93
17.96
-
9.16
-1.50
-
-36.43
6.74
-
PAT
180.50
135.52
33.19%
137.07
135.00
1.53%
120.63
-58.66
-
161.05
33.85
375.78%
PATM
11.07%
8.98%
8.59%
-10.84%
8.12%
-4.65%
11.45%
2.39%
EPS
9.18
6.20
48.06%
6.95
-0.96
-
6.14
-3.35
-
7.76
1.12
592.86%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
6,118.10
5,652.62
5,305.78
5,393.14
4,605.76
3,934.69
3,130.81
3,134.61
3,165.99
2,056.13
1,863.22
Net Sales Growth
8.06%
6.54%
-1.62%
17.10%
17.06%
25.68%
-0.12%
-0.99%
53.98%
10.35%
 
Cost Of Goods Sold
1,768.19
1,708.81
1,446.43
1,257.35
1,039.38
992.71
886.19
887.57
823.95
639.85
627.02
Gross Profit
4,349.91
3,943.81
3,859.35
4,135.79
3,566.38
2,941.98
2,244.62
2,247.04
2,342.04
1,416.28
1,236.20
GP Margin
71.10%
69.77%
72.74%
76.69%
77.43%
74.77%
71.69%
71.68%
73.97%
68.88%
66.35%
Total Expenditure
5,232.59
4,944.54
4,431.64
3,913.05
3,391.69
3,078.87
2,515.55
2,519.90
2,160.88
1,660.92
1,506.16
Power & Fuel Cost
-
151.54
120.84
118.72
102.40
88.86
70.35
64.20
58.89
43.31
32.07
% Of Sales
-
2.68%
2.28%
2.20%
2.22%
2.26%
2.25%
2.05%
1.86%
2.11%
1.72%
Employee Cost
-
1,169.13
1,133.00
1,051.17
906.44
746.69
622.81
558.83
472.85
306.76
247.00
% Of Sales
-
20.68%
21.35%
19.49%
19.68%
18.98%
19.89%
17.83%
14.94%
14.92%
13.26%
Manufacturing Exp.
-
409.37
379.15
372.18
368.41
269.25
244.53
289.79
271.51
263.38
272.44
% Of Sales
-
7.24%
7.15%
6.90%
8.00%
6.84%
7.81%
9.24%
8.58%
12.81%
14.62%
General & Admin Exp.
-
492.63
413.90
391.24
339.82
340.56
283.43
299.79
233.28
145.68
117.73
% Of Sales
-
8.72%
7.80%
7.25%
7.38%
8.66%
9.05%
9.56%
7.37%
7.09%
6.32%
Selling & Distn. Exp.
-
952.30
890.38
687.41
531.19
590.28
380.21
393.14
274.14
244.69
194.03
% Of Sales
-
16.85%
16.78%
12.75%
11.53%
15.00%
12.14%
12.54%
8.66%
11.90%
10.41%
Miscellaneous Exp.
-
60.76
47.94
34.98
104.05
50.52
28.03
26.58
26.26
17.26
194.03
% Of Sales
-
1.07%
0.90%
0.65%
2.26%
1.28%
0.90%
0.85%
0.83%
0.84%
0.85%
EBITDA
885.51
708.08
874.14
1,480.09
1,214.07
855.82
615.26
614.71
1,005.11
395.21
357.06
EBITDA Margin
14.47%
12.53%
16.48%
27.44%
26.36%
21.75%
19.65%
19.61%
31.75%
19.22%
19.16%
Other Income
25.60
3.04
50.49
87.48
13.88
27.14
34.87
2.58
8.83
12.09
4.44
Interest
59.62
50.17
17.73
16.02
27.16
18.41
3.40
5.23
5.43
3.81
10.40
Depreciation
277.31
275.43
286.78
183.47
157.32
115.23
105.46
82.97
72.21
44.41
40.49
PBT
574.18
385.52
620.12
1,368.08
1,043.47
749.32
541.27
529.09
936.30
359.07
310.61
Tax
-25.07
12.61
104.46
253.32
199.18
156.75
120.36
122.19
216.12
76.35
75.10
Tax Rate
-4.37%
3.27%
16.85%
18.52%
19.92%
20.92%
22.24%
23.09%
23.08%
21.26%
24.18%
PAT
599.25
341.99
520.94
1,114.76
828.76
593.65
420.72
406.99
720.18
282.72
235.51
PAT before Minority Interest
599.25
341.99
520.94
1,114.76
800.64
592.57
420.91
406.90
720.18
282.72
235.51
Minority Interest
0.00
0.00
0.00
0.00
28.12
1.08
-0.19
0.09
0.00
0.00
0.00
PAT Margin
9.79%
6.05%
9.82%
20.67%
17.99%
15.09%
13.44%
12.98%
22.75%
13.75%
12.64%
PAT Growth
143.89%
-34.35%
-53.27%
34.51%
39.60%
41.10%
3.37%
-43.49%
154.73%
20.05%
 
EPS
30.48
17.40
26.50
56.70
42.15
30.20
21.40
20.70
36.63
14.38
11.98

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
4,370.47
5,237.54
5,066.98
3,219.42
2,718.83
2,220.14
1,902.33
1,597.36
884.64
675.57
Share Capital
39.31
39.31
39.31
37.70
37.70
37.70
37.70
37.70
37.70
37.70
Total Reserves
4,331.16
5,198.23
5,027.67
3,181.72
2,681.13
2,182.44
1,864.63
1,559.66
846.94
637.87
Non-Current Liabilities
52.42
162.07
361.16
1,046.98
570.06
576.20
94.15
84.02
72.44
94.32
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
18.80
41.95
Unsecured Loans
0.00
0.00
199.89
886.99
499.30
500.00
0.00
0.00
0.00
10.27
Long Term Provisions
106.20
95.82
85.52
74.51
52.03
40.76
57.22
28.23
9.36
6.68
Current Liabilities
1,640.80
1,830.59
1,533.26
1,751.61
1,663.65
1,267.18
813.96
944.19
684.09
602.51
Trade Payables
679.81
706.39
668.78
625.93
644.34
759.32
500.73
565.65
324.94
288.44
Other Current Liabilities
251.19
516.51
557.92
226.98
380.19
142.89
81.28
51.80
44.56
60.62
Short Term Borrowings
635.87
430.00
0.02
860.50
429.13
207.78
88.51
113.71
219.70
25.42
Short Term Provisions
73.93
177.69
306.54
38.20
209.99
157.19
143.44
213.03
94.88
228.02
Total Liabilities
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
1,641.17
1,372.40
Net Block
2,398.45
1,797.85
1,788.42
1,551.84
1,158.45
993.38
799.40
708.09
546.87
396.96
Gross Block
3,706.86
2,840.33
2,545.39
2,132.41
1,522.57
1,242.47
950.09
1,093.63
861.06
665.08
Accumulated Depreciation
1,308.41
1,042.48
756.97
580.57
364.12
249.09
150.69
385.54
314.19
268.12
Non Current Assets
3,149.80
4,255.37
4,056.96
3,526.30
2,820.02
2,116.31
1,316.80
917.30
750.43
515.81
Capital Work in Progress
601.28
2,304.24
2,182.53
1,846.18
1,551.23
1,010.15
396.28
92.52
83.14
20.67
Non Current Investment
96.33
118.40
49.31
17.62
48.76
41.64
49.88
53.43
2.26
3.36
Long Term Loans & Adv.
53.74
34.88
36.70
110.66
61.58
71.14
71.24
29.96
118.15
94.82
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
33.30
0.00
0.00
Current Assets
2,913.89
2,974.83
2,904.44
2,462.75
2,131.73
1,947.52
1,493.75
1,708.27
890.74
856.59
Current Investments
0.00
0.00
186.97
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,475.27
1,609.70
1,486.15
1,187.54
967.27
733.93
632.75
569.79
382.77
310.78
Sundry Debtors
1,046.41
807.13
348.60
864.75
488.92
526.34
338.82
350.48
361.17
273.37
Cash & Bank
82.27
69.43
105.84
80.75
205.62
89.92
159.60
450.83
26.83
23.96
Other Current Assets
309.94
51.65
78.67
28.10
469.92
597.33
362.58
337.17
119.98
248.48
Short Term Loans & Adv.
254.62
436.92
698.21
301.61
451.71
569.84
355.02
330.08
119.98
248.48
Net Current Assets
1,273.09
1,144.24
1,371.18
711.14
468.08
680.34
679.79
764.08
206.65
254.08
Total Assets
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
1,641.17
1,372.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
723.95
552.35
1,463.38
449.15
811.97
312.42
328.55
947.65
171.76
239.97
PBT
354.59
625.39
1,368.08
999.82
749.32
541.27
529.09
936.31
359.07
310.61
Adjustment
487.63
417.75
102.42
278.28
117.57
87.12
83.06
69.45
44.61
69.76
Changes in Working Capital
-57.57
-367.36
238.30
-592.84
111.56
-180.85
-165.64
138.90
-162.50
-71.53
Cash after chg. in Working capital
784.65
675.78
1,708.80
685.26
978.45
447.54
446.51
1,144.66
241.18
308.84
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-60.70
-123.43
-245.42
-236.11
-166.48
-135.12
-117.96
-197.01
-69.42
-68.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-447.59
-371.97
-838.80
-731.63
-755.60
-884.38
-485.91
-306.80
-255.61
-81.06
Net Fixed Assets
830.36
-402.51
-1,303.18
-789.71
-638.70
-606.86
-121.60
-288.80
-200.26
-81.01
Net Investments
-9.91
123.73
490.16
-326.86
-207.50
-195.85
-65.58
-4.13
0.00
-29.98
Others
-1,268.04
-93.19
-25.78
384.94
90.60
-81.67
-298.73
-13.87
-55.35
29.93
Cash from Financing Activity
-261.96
-217.35
-597.42
154.85
59.03
502.63
-128.88
-224.30
86.72
-151.06
Net Cash Inflow / Outflow
14.40
-36.97
27.16
-127.63
115.40
-69.33
-286.24
416.55
2.86
7.86
Opening Cash & Equivalents
61.09
98.06
71.83
199.06
83.74
153.07
439.32
22.77
23.96
16.11
Closing Cash & Equivalent
75.48
61.09
98.06
71.84
199.07
83.74
153.08
439.32
26.83
23.96

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
222.36
266.47
257.80
170.79
144.24
117.78
100.92
84.74
46.93
35.84
ROA
5.15%
7.34%
17.22%
14.64%
13.15%
12.25%
14.97%
33.76%
18.76%
18.79%
ROE
7.12%
10.11%
26.91%
26.97%
24.00%
20.42%
23.25%
58.03%
36.24%
39.97%
ROCE
7.44%
11.25%
26.28%
23.30%
22.66%
22.15%
28.87%
65.87%
37.54%
43.54%
Fixed Asset Turnover
1.73
1.97
2.31
2.52
2.85
2.86
3.07
3.24
2.71
3.02
Receivable days
59.84
39.75
41.06
53.64
47.09
50.43
40.13
41.02
55.91
49.38
Inventory Days
99.60
106.49
90.48
85.38
78.91
79.67
70.01
54.91
61.11
56.34
Payable days
148.05
173.51
187.92
69.87
88.23
98.47
84.03
80.04
69.83
66.49
Cash Conversion Cycle
11.40
-27.27
-56.39
69.15
37.76
31.63
26.12
15.89
47.19
39.23
Total Debt/Equity
0.15
0.12
0.10
0.54
0.42
0.32
0.05
0.07
0.30
0.16
Interest Cover
8.07
36.27
86.40
37.81
41.70
160.20
102.16
173.43
95.30
30.87

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Alembic Pharma gets tentative USFDA’s nod for breast cancer drug
    1st Apr 2024, 16:09 PM

    It is the generic equivalent of Novartis' Kisqali tablets

    Read More
  • USFDA conducts inspection at Alembic Pharmaceuticals’ Oncology Formulation Facility
    9th Mar 2024, 15:03 PM

    The USFDA issued a Form 483 with four procedural observations

    Read More
  • Alembic Pharma - Quarterly Results
    5th Feb 2024, 14:17 PM

    Read More
  • Alembic Pharmaceuticals to invest $1.0 million in RIGImmune
    19th Jan 2024, 14:11 PM

    This investment will help the company to get into niche segment of new chemical entities

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.